OBJECTIVES: Studies of neurocognitively elite older adults, termed SuperAgers, have identified clinical predictors and neurobiological indicators of resilience against age-related neurocognitive decline. Despite rising rates of older persons living with HIV (PLWH), SuperAging (SA) in PLWH remains undefined. We aimed to establish neuropsychological criteria for SA in PLWH and examined clinically relevant correlates of SA. METHODS: 734 PLWH and 123 HIV-uninfected participants between 50 and 64 years of age underwent neuropsychological and neuromedical evaluations. SA was defined as demographically corrected (i.e., sex, race/ethnicity, education) global neurocognitive performance within normal range for 25-year-olds. Remaining participants were labeled cognitively normal (CN) or impaired (CI) based on actual age. Chi-square and analysis of variance tests examined HIV group differences on neurocognitive status and demographics. Within PLWH, neurocognitive status differences were tested on HIV disease characteristics, medical comorbidities, and everyday functioning. Multinomial logistic regression explored independent predictors of neurocognitive status. RESULTS: Neurocognitive status rates and demographic characteristics differed between PLWH (SA=17%; CN=38%; CI=45%) and HIV-uninfected participants (SA=35%; CN=55%; CI=11%). In PLWH, neurocognitive groups were comparable on demographic and HIV disease characteristics. Younger age, higher verbal IQ, absence of diabetes, fewer depressive symptoms, and lifetime cannabis use disorder increased likelihood of SA. SA reported increased independence in everyday functioning, employment, and health-related quality of life than non-SA. CONCLUSIONS: Despite combined neurological risk of aging and HIV, youthful neurocognitive performance is possible for older PLWH. SA relates to improved real-world functioning and may be better explained by cognitive reserve and maintenance of cardiometabolic and mental health than HIV disease severity. Future research investigating biomarker and lifestyle (e.g., physical activity) correlates of SA may help identify modifiable neuroprotective factors against HIV-related neurobiological aging. (JINS, 2019, 25, 507-519).
OBJECTIVES: Studies of neurocognitively elite older adults, termed SuperAgers, have identified clinical predictors and neurobiological indicators of resilience against age-related neurocognitive decline. Despite rising rates of older persons living with HIV (PLWH), SuperAging (SA) in PLWH remains undefined. We aimed to establish neuropsychological criteria for SA in PLWH and examined clinically relevant correlates of SA. METHODS: 734 PLWH and 123 HIV-uninfectedparticipants between 50 and 64 years of age underwent neuropsychological and neuromedical evaluations. SA was defined as demographically corrected (i.e., sex, race/ethnicity, education) global neurocognitive performance within normal range for 25-year-olds. Remaining participants were labeled cognitively normal (CN) or impaired (CI) based on actual age. Chi-square and analysis of variance tests examined HIV group differences on neurocognitive status and demographics. Within PLWH, neurocognitive status differences were tested on HIV disease characteristics, medical comorbidities, and everyday functioning. Multinomial logistic regression explored independent predictors of neurocognitive status. RESULTS: Neurocognitive status rates and demographic characteristics differed between PLWH (SA=17%; CN=38%; CI=45%) and HIV-uninfectedparticipants (SA=35%; CN=55%; CI=11%). In PLWH, neurocognitive groups were comparable on demographic and HIV disease characteristics. Younger age, higher verbal IQ, absence of diabetes, fewer depressive symptoms, and lifetime cannabis use disorder increased likelihood of SA. SA reported increased independence in everyday functioning, employment, and health-related quality of life than non-SA. CONCLUSIONS: Despite combined neurological risk of aging and HIV, youthful neurocognitive performance is possible for older PLWH. SA relates to improved real-world functioning and may be better explained by cognitive reserve and maintenance of cardiometabolic and mental health than HIV disease severity. Future research investigating biomarker and lifestyle (e.g., physical activity) correlates of SA may help identify modifiable neuroprotective factors against HIV-related neurobiological aging. (JINS, 2019, 25, 507-519).
Authors: Giovanni Marsicano; Sharon Goodenough; Krisztina Monory; Heike Hermann; Matthias Eder; Astrid Cannich; Shahnaz C Azad; Maria Grazia Cascio; Silvia Ortega Gutiérrez; Mario van der Stelt; Maria Luz López-Rodriguez; Emilio Casanova; Günther Schütz; Walter Zieglgänsberger; Vincenzo Di Marzo; Christian Behl; Beat Lutz Journal: Science Date: 2003-10-03 Impact factor: 47.728
Authors: Catherine L Carey; Steven Paul Woods; Raul Gonzalez; Emily Conover; Thomas D Marcotte; Igor Grant; Robert K Heaton Journal: J Clin Exp Neuropsychol Date: 2004-05 Impact factor: 2.475
Authors: Victor G Valcour; Cecilia M Shikuma; Bruce T Shiramizu; Andrew E Williams; Michael R Watters; Pamela W Poff; John S Grove; Ola A Selnes; Ned C Sacktor Journal: J Acquir Immune Defic Syndr Date: 2005-01-01 Impact factor: 3.731
Authors: Victor G Valcour; Ned C Sacktor; Robert H Paul; Michael R Watters; Ola A Selnes; Bruce T Shiramizu; Andrew E Williams; Cecilia M Shikuma Journal: J Acquir Immune Defic Syndr Date: 2006-12-01 Impact factor: 3.731
Authors: R K Heaton; N Temkin; S Dikmen; N Avitable; M J Taylor; T D Marcotte; I Grant Journal: Arch Clin Neuropsychol Date: 2001-01 Impact factor: 2.813
Authors: Robert K Heaton; Thomas D Marcotte; Monica Rivera Mindt; Joseph Sadek; David J Moore; Heather Bentley; J Allen McCutchan; Carla Reicks; Igor Grant Journal: J Int Neuropsychol Soc Date: 2004-05 Impact factor: 2.892
Authors: V Valcour; C Shikuma; B Shiramizu; M Watters; P Poff; O Selnes; P Holck; J Grove; N Sacktor Journal: Neurology Date: 2004-09-14 Impact factor: 9.910
Authors: Stephanie Shiau; Alexis A Bender; Jane A O'Halloran; Erin Sundermann; Juhi Aggarwal; Keri N Althoff; Jason V Baker; Steven Deeks; Linda P Fried; Stephen Karpiak; Maile Y Karris; Thomas D Marcotte; Jean B Nachega; Joseph B Margolick; Kristine M Erlandson; David J Moore Journal: AIDS Res Hum Retroviruses Date: 2020-09-23 Impact factor: 2.205
Authors: Rowan Saloner; Judith D Lobo; Emily W Paolillo; Laura M Campbell; Scott L Letendre; Mariana Cherner; Igor Grant; Robert K Heaton; Ronald J Ellis; David J Moore Journal: J Acquir Immune Defic Syndr Date: 2022-08-01 Impact factor: 3.771
Authors: Rowan Saloner; Jerel Adam Fields; Maria Cecilia Garibaldi Marcondes; Jennifer E Iudicello; Sofie von Känel; Mariana Cherner; Scott L Letendre; Marcus Kaul; Igor Grant Journal: J Neuroimmune Pharmacol Date: 2020-09-15 Impact factor: 4.147
Authors: Zeping Wang; Maura M Manion; Elizabeth Laidlaw; Adam Rupert; Chuen-Yen Lau; Bryan R Smith; Avindra Nath; Irini Sereti; Dima A Hammoud Journal: AIDS Date: 2021-07-01 Impact factor: 4.632
Authors: Drenna Waldrop; Crista Irwin; W Chance Nicholson; Cheryl A Lee; Allison Webel; Pariya L Fazeli; David E Vance Journal: J Assoc Nurses AIDS Care Date: 2021 May-Jun 01 Impact factor: 1.809
Authors: Raha M Dastgheyb; Alison S Buchholz; Kathryn C Fitzgerald; Yanxun Xu; Dionna W Williams; Gayle Springer; Kathryn Anastos; Deborah R Gustafson; Amanda B Spence; Adaora A Adimora; Drenna Waldrop; David E Vance; Joel Milam; Hector Bolivar; Kathleen M Weber; Norman J Haughey; Pauline M Maki; Leah H Rubin Journal: Front Neurol Date: 2021-02-11 Impact factor: 4.003